![[SaNOtize in Business Wire] SaNOtize broadcasts $24 million in Sequence B funding to advance its nitric oxide-based therapeutics, together with nasal spray for the remedy and prevention of COVID-19](https://blog.ourcrowd.com/wp-content/uploads/2021/12/business-wire-new-150x150-1.jpg "[SaNOtize in Business Wire] SaNOtize broadcasts $24 million in Sequence B funding to advance its nitric oxide-based therapeutics, together with nasal spray for the remedy and prevention of COVID-19")
VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Analysis & Growth Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics firm, at the moment introduced an oversubscribed $24 million Sequence B funding to advance its nitric oxide-based therapeutics pipeline. The lead remedy within the pipeline is the corporate’s nitric oxide nasal spray (NONS™), proven in scientific research to deal with and stop COVID-19 an infection, together with a latest Section 3 examine printed in The Lancet Regional Well being Southeast Asia. The brand new funding spherical was co-led by Horizons Ventures and OurCrowd, with participation from ABC Worldwide, and permits SaNOtize to broaden its analysis program, together with its ongoing world Section 3 NONS prevention scientific examine with plans to recruit as much as 3,000 individuals in Canada and Sri Lanka.
Learn extra right here.
